Effect of CHF5993 pMDI (extrafine Beclometasone Dipropionate:BDP,Formoterol Fumarate:FF,Glycopyrronium Bromide:GB) on Clinically Important Deteriorations (CID) in COPD: post-hoc analysis of TRINITY study Source: International Congress 2017 – Inhalers and their use Year: 2017
CHF5993 pMDI (extrafine Beclometasone Dipropionate:BDP, Formoterol Fumarate:FF, Glycopyrronium Bromide:GB) reduces Clinically Important Deteriorations (CID) in COPD: post-hoc analysis of TRILOGY study. Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017
Effect of patient age on response to nebulised salbutamol or ipratropium bromide Source: Annual Congress 2012 - Going with the flow: assessment and evaluation of airway function and its role in patient management Year: 2012
Nonbronchial effects of ipratropium bromide: is there interference with micturation? Source: Eur Respir J 2001; 18: Suppl. 33, 53s Year: 2001
A comparison of early bronchodilating responses of Salbutamol, Ipratropium bromide, and the combination of Ipratropium bromide-Salbutamol in stable patients with COPD or asthma Source: Eur Respir J 2002; 20: Suppl. 38, 246s Year: 2002
How long should tiotropium bromide be suspended before methacholine challenge? Source: Eur Respir J 2006; 28: Suppl. 50, 218s Year: 2006
Efficacy of ipratropium bromide/ fenoterol hydrobromide HFA and CFC propellant inhalers in patients with COPD Source: Eur Respir J 2003; 22: Suppl. 45, 52s Year: 2003
Pulmonary function and bronchodilator response to albuterol, ipratropium bromide and association of albuterol and ipratropium bromide in children with cystic fibrosis (CF) Source: Eur Respir J 2003; 22: Suppl. 45, 229s Year: 2003
Ipratropium bromide pre-treatment influences recovery after methacholine induced bronchospasm Source: Eur Respir J 2002; 20: Suppl. 38, 505s Year: 2002
Cardiopulmonary effects of inhaled ipratropium bromide and its combination with fenoterol in patients with bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 58s Year: 2002
Reversibility effects of ipratropium bromide and terbutalin sulphate in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 72s Year: 2001
Long-lasting interaction study between RPL554 and glycopyrronium bromide on human isolated bronchi Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
Interaction between RPL554 and glycopyrronium bromide in small human airways Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
Comparison of nebulized ipratropium bromide with salbutamol versus salbutamol alone in acute asthma exacerbation in children Source: Eur Respir J 2004; 24: Suppl. 48, 167s Year: 2004
Airway tone during exercise in healthy subjects: effects of salbutamol and ipratropium bromide Source: Eur Respir J 2003; 22: Suppl. 45, 89s Year: 2003
Efficiency of ipratropium bromide and salbutamol deposition in the lung delivered via a soft-spray inhaler or chlorofluorocarbon metered-dose inhaler Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Improved delivery of fenoterol plus ipratropium bromide using Respimat(R) compared with a conventional metered dose inhaler Source: Eur Respir J 2001; 17: 225-232 Year: 2001
Salbutamol or ipratropium bromide: does gender and age influence the response to drugs? Source: Virtual Congress 2021 – Lung function testing in the management of obstructive diseases Year: 2021
Protection against methacholine-induced bronchospasm: salbutamol pMDI versus Clickhaler(R) DPI Source: Eur Respir J 2003; 21: 816-820 Year: 2003
Assessment of Pulmonary Deposition between two formulations of Salmeterol xinafoate/Fluticasone propionate HFA pMDI 25/125 mcg Source: International Congress 2017 – Inhalers and their use Year: 2017